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Background: Previous studies have revealed altered expression of epidermal growth factor receptor (EGFR)-family
members and their endogenous inhibitor leucine-rich and immunoglobulin-like domains 1 (LRIG1) in renal cell
carcinoma (RCC). In this study, we analyzed the gene expression levels of EGFR-family members and LRIG1, and
their possible associations with clinical parameters in various types of RCC.
Methods: Gene expression levels of EGFR–family members and LRIG1 were analyzed in 104 RCC samples, including
81 clear cell RCC (ccRCC), 15 papillary RCC (pRCC), and 7 chromophobe RCC (chRCC) by quantitative real-time
RT-PCR. Associations between gene expression levels and clinical data, including tumor grade, stage, and patient
survival were statistically assessed.
Results: Compared to kidney cortex, EGFR was up-regulated in ccRCC and pRCC, LRIG1 and ERBB2 were down-regulated
in ccRCC, and ERBB4 was strongly down-regulated in all RCC types. ERBB3 expression did not differ between RCC types or
between RCC and the kidney cortex. The expression of the analyzed genes did not correlate with patient outcome.
Conclusions: This study revealed that the previously described up-regulation of EGFR and down-regulation of ERBB4
occurred in all analyzed RCC types, whereas down-regulation of ERBB2 and LRIG1 was only present in ccRCC. These
observations illustrate the need to evaluate the different RCC types individually when analyzing molecules of interest and
potential biological markers.
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Background
Renal cell carcinoma (RCC) consists of various tumor
types [1]; clear cell RCC (ccRCC) accounts for approxi-
mately 70-80 % of the RCCs, papillary RCC (pRCC) for
10-15 % of cases, chromophobe RCC (chRCC) for
approximately 5 %, and collecting duct carcinoma for
less than 1 % of RCCs. Approximately 4-5 % of RCCs do
not fit the histopathological criteria and are referred to
as unclassified carcinomas [1]. The RCC types represent
tumor groups with different genetic and molecular
properties, as reviewed in [2] and [3]. When RCC types
are analyzed collectively, the results predominantly
reflect the properties of ccRCC, since this type accounts* Correspondence: marcus.thomasson@onkologi.umu.se
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provided the original work is properly cited.for the majority of RCC cases. Previous studies have
revealed altered expression of epidermal growth factor
(EGF) receptor (EGFR)-family members and their
endogenous inhibitor leucine-rich and immunoglobulin-
like domains 1 (LRIG1) in renal cell carcinoma (RCC).
The EGFR family consists of four receptor tyrosine
kinases, EGFR (ERBB1, HER1), ERBB2 (HER2, neu),
ERBB3 (HER3), and ERBB4 (HER4) [4], of which down-
stream intracellular signaling pathways regulate cell pro-
liferation, differentiation, and migration [5]. LRIG1 [6]
negatively regulates all four members of the EGFR-family
[7–10]. LRIG1 is also a negative regulator of the MET -
and RET -receptor tyrosine kinases [11,12]. LRIG1 is
down-regulated in several cancers and cancer cell lines,
including breast cancer and squamous cell carcinoma of
the skin and uterine cervix, where low LRIG1 expression
correlates with poor patient survival [13–17].tral Ltd. This is an Open Access article distributed under the terms of the Creative Commons
icenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium,
Table 1 Characteristics of the patients and tumors
included in the study
Total no. of patients 104
Sex male/female 56/48
Age in years median (range) 65 (25–85)
Tumor diameter in mm median (range) 80 (30–250)
Survival in months Range 0-130
Tumor stage (WHO) I 26
(As derived from TNM) II 15
III 30
IV 33








Patients with known metastasis at diagnosis 35
Patients who died from the disease 57
Patients dead from other causes 16
Patients alive at last follow-up (with disease) 31 (3)
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family members and LRIG1 in a limited number of RCC-
patients [18,19]. Here, we extended these studies to a larger
patient cohort, and analyzed the RCC types individually.
Methods
In this study we analyzed tumor samples from 104 patients
who underwent nephrectomy at the Department of Urology,
Umeå University Hospital, between the years 1986 and 1999
(Table 1). These tumors included 81 ccRCC, 15 pRCC, 7
chRCC, and 1 unclassified carcinoma. Additionally, speci-
mens of histologically verified non-neoplastic kidney cor-
tex were obtained from 27 of the nephrectomized kidneys.
RNA was prepared and quantitative real-time reverse tran-
scription- (RT-) PCR of EGFR, ERBB2, ERBB3, ERBB4,Table 2 Significant differences in mRNA expression between
All RCC combined* ccRCC* pRCC*
EGFR < 0.001 0.001 0.016
ErbB2 0.003 0.001 NS
ErbB3 NS NS NS
ErbB4 0.001 < 0.001 0.001
LRIG1 NS 0.015 NS
* P-values were calculated in comparison to kidney cortex using the Mann–Whitney
† Comparison of the significant differences between the RCC types was performed
NS, non-significant.LRIG1, and RN18S1 (18 S rRNA) was performed as
previously described [18,19]. To correct for differences
in RNA quality and quantity, apparent levels of RN18S1
were used to normalize the EGFR, ERBB2-4, and LRIG1
values in each respective RNA sample. To test the
reliability of the analysis, all five protein encoding
genes were analyzed five times for three different
samples. The maximum coefficient of variation and
the standard deviation, expressed as a percentage of
the mean, was 22 %. Patients provided informed con-
sent for the use of both their tumor material and
clinical data for studies. This study was approved by
the research ethics committee at Umeå University
Medical Faculty (No 02–340).
Statistical analysis was performed using nonparametric
statistics, as normal distribution of the data could not
be assumed. For comparisons between two groups,
the Mann–Whitney U-test was used. Comparisons of
more than two groups were performed using the
Kruskal-Wallis test. Comparisons between coupled
samples were performed using the Wilcoxon signed-
rank test. Correlations were analyzed according to
Spearman’s rank correlation. Survival analysis was per-
formed by first comparing patients with mRNA ex-
pression levels either above or below the median and
then subjecting the data to Kaplan-Meier analysis by
log-rank test. All P-values were two-sided. All calcula-
tions were performed using SPSS 14.0 software.
Results
The expression of EGFR was higher in all RCC types
combined compared to kidney cortex tissue (P< 0.001)
(Table 2). This up-regulation was significant for both
ccRCC (P< 0.001) and pRCC (P = 0.016), but not for
chRCC (P = 0.257) (Figure 1A; Table 2). This is in line
with earlier findings by us and others [18,20–24].
ERBB2 expression was significantly reduced in all RCC
types combined compared to kidney cortex (P = 0.003);
however, reduced expression was only significant in ccRCC
(P=0.001) and not in pRCC or chRCC (Figure 1B). These
results indicate that the previously described down-
regulation of ERBB2 in RCC [19] is actually a result of
down-regulation in the ccRCCs.kidney cortex and the RCC types
chRCC* Altered expression Difference RCC types†
NS Up-regulation NS









Figure 1 Boxplots of the relative mRNA expression of the EGFR-family members and LRIG1 in both the kidney cortex and the RCC
types. Relative mRNA expression of EGFR, ERBB2, ERRB3, ERRB4, and LRIG1 was quantified in kidney cortex (n = 27), ccRCC (n = 81), pRCC (n = 15),
and chRCC (n = 7). (A) EGFR mRNA expression was elevated in ccRCC and pRCC compared to kidney cortex. (Increased expression in chRCC was
not significant, but expression levels were similar to other RCC groups.) (B) ERBB2 mRNA expression was significantly lower in ccRCC compared to
kidney cortex. In pRCC and chRCC, expression did not significantly differ from kidney cortex. (C) ERBB3 mRNA expression was not significantly
different between any of the RCC types compared to the kidney cortex. (D) ERBB4 mRNA expression was significantly reduced in all RCC types
compared to kidney cortex. (E) LRIG1 mRNA expression was significantly lower in ccRCC compared to kidney cortex. In pRCC and chRCC, LRIG1
expression did not significantly differ from kidney cortex. Outlier values are marked °. Significant differences compared to expression in the kidney
cortex are labeled (*) for P< 0.05 and (**) for P< 0.01.
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neoplastic kidney cortex, and there was no significant
expression difference between RCC types (Figure 1C).
ERBB4 expression was markedly lower in all the
different RCC types than in kidney cortex (P< 0.001).
There was no difference in ERBB4 expression between theRCC types (Figure 1D). Thus, the earlier described
down-regulation of ERBB4 in RCC [19] was here
shown to be prominent in all RCC types analyzed. In
fact, no ERBB4 expression could be detected in 51
out of the 104 tumors analyzed. This pronounced
down-regulation of ERBB4 may suggest an important
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development of RCC.
The expression of LRIG1 was reduced in ccRCC com-
pared to kidney cortex (P=0.020). The expression of LRIG1
in pRCC and chRCC was not significantly different from
that of kidney cortex (Figure 1E). Thus, the previously
described down-regulation of LRIG1 in RCC [18] was
restricted to ccRCC. This finding could indicate a tumor
suppressive role for LRIG1 in the context of ccRCC that is
not present or of reduced importance in other types of
RCC.
The expression levels of EGFR, ERBB2-4, and LRIG1
correlated significantly with each other in most cases
(Table 3). This was possibly due to LRIG1 expression being
up-regulated by receptor activation [7] or due to metholo-
dical issues, e.g. due to variation in the expression of the
reference gene, RN18S1. There was a non-significant trend
to an inverse correlation (R=−0.166 P= 0.058) between
the expression levels of EGFR and ERBB4. This results is
in line with EGFR being up-regulated and ERBB4 being
down-regulated in tumors.
The expression levels of ERBB3 within ccRCC were
inversely correlated with tumor grade and tumor size
(R =−0.287, P = 0.009 and R=−0.244, P = 0.027, respec-
tively). As expression of ERBB3 mRNA was low and did
not differ between tumors and kidney cortex or between
RCC types, the biological significance of this finding is
highly uncertain. No other significant correlation was
observed between the expression of EGFR-family mem-
bers or LRIG1 and the size, grade, or stage of the tumors.
Survival analysis comparing patients with tumors expres-
sing above or below median mRNA values of the five
genes revealed no significant difference in overall
survival or cancer specific survival, neither in ccRCC
patients or all RCC patients combined (Additional file 1
Figure S1). The patient groups for the other RCC typesTable 3 Correlation of mRNA expression levels between
the analyzed genes
EGFR ErbB2 ErbB3 ErbB4 LRIG1
EGFR CC 1.000 0.274* 0.425* −0.166 0,370*
P-value - 0.002 <0.001 0.058 <0.001
ErbB2 CC 0.274* 1.000 0.586* 0.375* 0.456*
P-value 0.002 - <0.001 <0.001 <0.001
ErbB3 CC 0.425* 0.586* 1.000 0.152 0.456
P-value <0.001 <0.001 - 0.082 0.000
ErbB4 CC −0.166 0.375* 0.152 1.000 0.277*
P-value 0.058 <0.001 0.082 - 0.001
LRIG1 CC 0.370* 0.456 0.456 0.277* 1.000
P-value <0.001 <0.001 <0.001 0.001 -
CC, Correlation coefficient according to Spearman.
*Significant with P-value <0.05.were too small for meaningful survival analyses. The
previously described and non-significant association
between LRIG1 expression and tumor grade and patient
survival [18] was not confirmed in the present and larger
study. Therefore, it appears that although LRIG1 may
possess a tumor suppressive function in ccRCC, it does
not appear to be an important prognostic factor in RCC.
Conclusions
This study demonstrated that the expression of EGFR,
ERBB3 and ERBB4 was similar throughout different
RCC types, whereas the expression of ERBB2 and
LRIG1 differed between the various types of RCC.
This demonstrates potentially important differences
and similarities in the expression of the EGFR-family
members and LRIG1 genes between different RCC
types. Up-regulated gene expression of EGFR compared to
kidney cortex was found in all RCC types analyzed. A
strong down-regulation of ERBB4 was observed in all
RCC types analyzed, while down-regulation of ERBB2 and
LRIG1 was found only in ccRCC. The biological and
clinical significance of these differences in gene expression
warrants further study.
Additional file
Additional file 1: Figure S1 Kaplan-Meier survival curves of cancer
specific survival comparing patients with tumors above and below
median expression of all five genes.
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